ZyVersa Therapeutics, Inc. reported impairment charges for the second quarter ended June 30, 2023. For the period, the company reported impairment of goodwill of $11,895,033.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.71 USD | -3.09% | +10.73% | -47.67% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-47.67% | 3.69M | |
+16.73% | 121B | |
+13.04% | 107B | |
-5.80% | 24.82B | |
+1.69% | 22.48B | |
-10.09% | 18.32B | |
-40.52% | 16.33B | |
-14.00% | 15.31B | |
+1.18% | 14.08B | |
+24.18% | 11.74B |
- Stock Market
- Equities
- ZVSA Stock
- News ZyVersa Therapeutics, Inc.
- ZyVersa Therapeutics, Inc. Reports Impairment Charges for the Second Quarter Ended June 30, 2023